REVA Medical
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|
Revenues | - | 3.0m | 8.0m | 20.0m |
% growth | - | - | 167 % | 150 % |
EBITDA | (16.2m) | (19.0m) | (16.0m) | (8.0m) |
% EBITDA margin | - | (633 %) | (200 %) | (40 %) |
Profit | 5.8m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Growth Equity VC | |
$42.0m | Late VC | ||
N/A | N/A | IPO | |
$25.0m | Post IPO Debt | ||
N/A | $34.6m | Post IPO Equity | |
* | $45.0m | Series B | |
Total Funding | €79.1m |
Recent News about REVA Medical
EditREVA Medical specializes in the development and commercialization of bioresorbable polymer technologies for vascular applications. The company primarily serves patients with coronary artery disease by providing an alternative to traditional metallic stents through its flagship product, the Fantom Encore. This drug-eluting bioresorbable vascular scaffold supports arteries during the healing process and gradually dissolves, allowing natural movement and function to return. Operating in the medical device market, REVA Medical targets healthcare providers and institutions that focus on cardiovascular treatments. The business model revolves around the research, development, and sale of its proprietary medical devices, generating revenue through product sales and potentially through licensing agreements.
Keywords: bioresorbable, vascular scaffolds, coronary artery disease, polymer technology, medical devices, Fantom Encore, cardiovascular, drug-eluting, healthcare providers, implantable devices.